UK markets closed

Bio Plus Co., Ltd (099430.KQ)

KOSDAQ - KOSDAQ Delayed price. Currency in KRW
Add to watchlist
6,400.00-40.00 (-0.62%)
At close: 03:30PM KST

Bio Plus Co., Ltd

Seongnam Woolim Lions Valley 2 cha A dong 1801 and 1802 ho
Sagimakgol-ro 45th Street 14 Jungwon-gu
Seongnam-si 13209
South Korea
82 3 1742 1898
https://www.ubioplus.co.kr

Sector(s)
Industry
Full-time employees35

Key executives

NameTitlePayExercisedYear born
Hyun-Kyu JungChief Executive OfficerN/AN/AN/A
Amounts are as of , and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in KRW.

Description

Bio Plus Co., Ltd engages in the research and development, production, and sale of bio products in South Korea. It offers dermal fillers under the SkinPlus – Hyal, Bio+ Dew, HyalDew, DeneB Classic, Stilea, and 3-Senses brand names. The company also provides medical products, including InterBlock, an absorbable anti-adhesion barrier; Synofil, a synovial fluid replacement; and Blad-Care, a solution to temporarily improve cystitis symptoms. In addition, it offers mesotherapy products, such as skin rejuvenation products under the Kiara Reju name; Slim Slimmer, a lipolysis solution; LumiDew, a whitening solution; JuveniHill, an anti-wrinkle solution; and hair scalp care, hair treatment, hair nutrition solutions under the BelloHa and BellaChe names, as well as cosmetics comprising heparinoid essence, EGF ball, and skin care gel under the La Bella name. The company was founded in 2003 and is based in Seongnam-si, South Korea.

Corporate governance

Bio Plus Co., Ltd’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.